Mark Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Mark Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-59,630	Closed	-$1.97M	–	55
2015 Q3	$1.97M	Buy	+59,630	New	+$2.48M	0.57%	35
2015 Q2	–	Sell	-32,628	Closed	-$1.06M	–	55
2015 Q1	$1.06M	Sell	32,628 -112,126	-77%	-$3.85M	0.28%	42
2014 Q4	$4.6M	Buy	144,754 +44,655	+45%	+$1.27M	1.23%	30
2014 Q3	$2.48M	Buy	100,099 +10,622	+12%	+$248K	0.68%	37
2014 Q2	$2.02M	Buy	89,477 +53,126	+146%	+$1.11M	0.54%	35
2014 Q1	$885K	Buy	+36,351	New	+$920K	0.27%	39

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Mark Asset Management's ACAD Position: Q4 2015 in Review

Mark Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2015, closing a stake of 59,630 shares — an estimated $1.97M sold.

Mark Asset Management first reported a position in ACAD in Q1 2014 and held it in 6 quarters. The position peaked at $4.6M in Q4 2014. 215 funds tracked by Wall St. Rank hold ACAD as of Q4 2015.

Mark Asset Management reported no remaining Acadia Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Mark Asset Management sold 59,630 Acadia Pharmaceuticals shares in Q4 2015, an estimated $1.97M.
Mark Asset Management first reported a position in Acadia Pharmaceuticals in Q1 2014 and held it in 6 quarters.
Mark Asset Management's Acadia Pharmaceuticals position peaked at $4.6M in Q4 2014.
215 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2015.

Based on Mark Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.